MYBMIM is an inhibitor for assembly of the molecular MYB:CBP/P300 complex. MYBMIM inhibits growth of leukemia cells.
MYBMIM (10-20 μM) inhibits proliferation (6 days) and induces apoptosis (48 h) in acute myeloid leukemia cells by downregulating anti-apoptotic Bcl2 gene expression[1].
MYBMIM (25 mg/kg, ip, twice a day for 14 days) impedes human leukemia progression in mouse xenograft models[1].
References:
[1]. Ramaswamy K, et al., Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun. 2018 Jan 9;9(1):110.